Cartalax / 20mg

---

1. Remove the vial from refrigerator storage  and allow to equilibrate at room temperature for 30 or more minutes.
2. Remove protective plastic cap, wipe top of Peptide and Bacteriostactic Water with alcohol to disinfect.
3. Draw 3.0 ml bacteriostatic water with a sterile syringe. All our vials are vacuum sealed, so when inserting syringe to add bacterioststic water hold plunger so it does not shoot the water into the peptide or vial.
4. Inject very slowly down the inside vial wall; avoid foaming.
5. Gently swirl/roll until dissolved—solution should be clear (do not shake).
6. Refrigerate at 2–8 °C (35.6–46.4 °F).

•  Frequency: Subcutaneous, once daily. 
• Cycle Length: 8–12 weeks; optional extension to 16 weeks. With 4 weeks off.

           Week/Phase      Daily Dose (mcg / mg)      Units (per injection) (mL)

             Weeks 1–2         2,000 mcg (2.0 mg)                30 units (0.30 mL)

             Weeks 3–4         3,000 mcg (3.0 mg)                45 units (0.45 mL)

             Weeks 5–8         4,000 mcg (4.0 mg)                60 units (0.60 mL)

            Weeks 9–12        5,000 mcg (5.0 mg)                75 units (0.75 mL) 

• So from a research-protocol standpoint, morning or evening is reasonable; consistency from day to  day matters more than the clock time. 

Cartalax (Ala‑Glu‑Asp) is classified among the Khavinson bioregulatory peptides—ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha‑1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki‑67 (a proliferation marker), increase SIRT‑1/SIRT‑6 expression, reduce p53 and caspase‑3 activity (pro‑apoptotic signals), and inhibit MMP‑9 synthesis (an enzyme linked to extracellular matrix degradation).

Observations from preclinical literature.

• May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures.
• Preclinical data suggest modulation of extracellular matrix homeostasis via MMP‑9 inhibition and collagen‑related gene expression.
• General tolerability: Khavinson bioregulator peptides have been described as well tolerated in observational settings; occasional mild injection‑site reactions (redness, itch) may occur with subcutaneous administration.
• Limitations: No large‑scale human RCTs; most data derive from in vitro or rodent models.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.